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Aire’s partnerships: An answer for many
questions and new questions in search of
answers
The focus of this perspective is the recent publication
by Abramson et al. (1) on the role of the Aire
(Autoimmune Regulator), which is a transcription
factor involved in promoting the surveillance of self-
antigens and the maintenance of immune tolerance.
This protein is mainly expressed in the medulla
of the thymus and is important in the prevention
of autoimmune disease including Type 1 diabetes
(T1D). In humans, a defective AIRE causes
Polyglandular Autoimmune Syndrome (APS) type
I or Autoimmune Polyendocrinopathy-Candidiasis-
Ectodermal Dystrophy (APECED), a rare autosomal
recessive disorder involving multiple endocrine organs
(4,5). APS-I is diagnosed when at least two of the
following three clinical manifestations of this disease
are identified: i) Chronic mucocutaneous candidiasis;
ii) Hypoadrenocorticism iii) Hypoparathyroidism.
APS-I has its peak of incidence in early childhood
and its frequency is similar in both females and
males, while APS-II is more frequent in middle age,
more commonly associated with diabetes mellitus and
without mutations in AIRE. Although less frequent
in APS-I, other endocrine features of this syndrome
include T1D as well as testicular or ovarian failure.
Alopecia, vitiligo pernicious anemia and chronic active
hepatitis can also occur in APS-I and all likely share a
common autoimmune etiology. The relevance of Aire
has been underscored by inactivating mutations of
Aire in mouse models of a polyendocrine autoimmune
disease (2, 3), which mimic the clinical features
of APS-I.
Abramson’s et al. publication (1) offers a new
relevant insight to understand the pathophysiology
of autoimmune endocrine diseases, including T1D.
Whereas the paper addresses normal physiological
interactions of Aire, it also becomes clear that
modifications in these interactions can lead to loss
of tolerance in autoimmune diseases. Although the
specific role of Aire in T1D has not been completely
elucidated, it is well documented that T1D is an
autoimmune disease characterized by loss of tolerance
to self-antigens; it is this loss of tolerance which
leads to the T-cell mediated destruction of β cells. In
this context, the work of Abramson and coworkers
(1), when taken together with what is known in
diseases related to Aire inactivation, provides a
thought-provoking framework of information that can
enlighten our understanding of the pathogenesis of
T1D and provide eventual avenues for therapy.
Regulation of normal tolerance to potential
self-antigens is essential for understanding the
pathophysiology of autoimmune diseases. Negative
selection of self-reactive T-cells in the thymus is critical
for immune tolerance and requires surveillance of self-
antigens. A key component of this tolerance is the
function of thymic medullary epithelial cells (MECs),
which possess the ability to ectopically transcribe
‘‘promiscuously’’ a large number of antigens normally
expressed in peripheral organs. Nagamine and
collaborators (6) and the Finnish-German APECED
Consortium (7) independently identified the gene
responsible for APECED and designated it AIRE
(Autoimmune Regulator). However, the specific
molecular interactions of Aire to modulate self-
antigen expression have not been elucidated in detail.
The publication by Abramson et al(1) addresses the
potential multiple intracellular roles of Aire. As
the authors state, and as also described in the
accompanying commentary by Kyewski and Peterson
(8), the pleiotropic effects of Aire, combined with the
structure of Aire itself, strongly suggested that Aire
does not act as a traditional transcription factor. The
work presented (1), indicates that Aire acts through a
variety of partners and pathways that can be grouped
into four major functional mechanisms encompassing
(i) nuclear transport, (ii) chromatin binding/structure,
(iii) transcription and (iv) pre-mRNA processing.
Their results (1) also imply that Aire interacts with
expression of gene sequences through recognition of
hypomethylated H3 tails. This suggests that Aire
interacts with epigenetic processes in expression of
self-antigens. Additionally, the data indicate that Aire
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would promote stabilization of short-lived pre-mRNA
through proper splicing and in turn, would contribute
to increases in mature mRNA.
The broad range of actions and interactions of Aire
may explain the diversity of phenotypes produced
by its inactivation, as evidenced in mouse models of
diverse backgrounds (2, 3, 9). There may be different
susceptibilities to autoimmunity due to epigenomic
structure. While the relevance of Aire mutations in
Type 1 APS is established and constitutes a model for
the loss of Aire function, the elucidation of role of
Aire in Type 2 APS, which includes subpopulations
with T1D, has proven elusive. There are gender-
associated changes in incidence of type 1 diabetes in
type 2 APS, where prevalence is higher in females
(10, 11). Gender-related differences in methylation
have been described in health (12) and in diseases
such as cancer (13) and diabetes (14, 15). It is
possible that epigenetic factors like methylation may
influence Aire and autoimmune diabetes. Another
possibility related to the action of Aire and to T1D is
RNA stability promotion. RNA stability in pancreatic
function has received growing interest (16). In Aire
deficiency or impaired function, defective pre-mRNA
processing and subsequent RNA instability may lower
expression of relevant transcription factors. This could
reduce T1D-associated gene expression and lead to
autoimmunity if Aire-expressing MECs are affected.
The suggested mechanisms of action of Aire,
described in Figure 7 of the publication by Abramson
(1), depict a sequential multiplicity of interactions.
These range from recognition of hypomethylated loci,
to the optimization of transcription of DNA coding
for weakly expressed self-antigens, to subsequent
stabilization of mRNA transcripts. However, as
the authors acknowledge, the figure describes a
speculative model in need of testing and confirmation
through rigorous research. Additionally, as indicated
by the commentary by Kyweski and Peterson (8),
the experimental work conducted by Abramson and
coworkers (1), mainly describes stable molecular
interactions and may have missed transient or weak
molecular partnerships.
Conclusions
The article provides a set of data that can be
extrapolated into thought-provoking and conceptually
interesting possibilities to address the loss of tolerance
in the development of T1D diabetes and also
other endocrine-related autoimmune diseases. There
is clearly much additional work that needs to be
done before the role of Aire in autoimmunity can
be fully elucidated. However, the work of Abramson
and coworkers (1) reviewed here, does provide a
fresh conceptual framework to help understand
the complexities of maintenance of tolerance and
the molecular epigenetic etiology of autoimmune
diseases. This is another example along with previously
published observations (17) suggesting that a diabetes-
prone MHC genotype is not absolutely necessary
to cause endocrine-specific autoimmunity including
autoimmune diabetes. The ability to present ectopic
autoantigens at sufficiently high levels to induce
immunologic tolerance in the thymus could be a matter
of threshold, and AIRE may play a crucial role
in controlling this threshold. This concept begs for
experimental demonstration.
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